Mersana Therapeutics to Present at Upcoming Investor Conferences
September 07 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that members of
management will present at three upcoming investor conferences.
Details are as follows:
Baird 2021 Global
Healthcare Conference |
Format: |
Fireside Chat |
Date/Time: |
Tuesday, September 14, 2021,
at 8:30 a.m. ET |
|
|
Morgan Stanley
19th Annual Global Healthcare Conference |
Format: |
Fireside Chat |
Date/Time: |
Wednesday, September 15, 2021,
at 1:15 p.m. ET |
|
|
2021 Cantor
Virtual Global Healthcare Conference |
Format: |
Presentation |
Date/Time: |
Tuesday, September 28, 2021,
at 4:00 p.m. ET |
A live webcast of these events will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for
approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1 umbrella study in combination with other ovarian
cancer therapies. UpRi is also being studied in the expansion
portion of a Phase 1 proof-of-concept clinical study. XMT-1592,
Mersana’s second ADC product candidate targeting NaPi2b-expressing
tumors, was created using Mersana’s customizable and homogeneous
Dolasynthen platform and is in the dose escalation portion of a
Phase 1 proof-of-concept clinical study. The Company’s early-stage
programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as
well as XMT-2056, a STING-agonist ADC developed using the Company’s
Immunosynthen platform. In addition, multiple partners are using
Mersana’s Dolaflexin platform to advance their ADC pipelines. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Contact:
Investor & Media ContactSarah
Carmody617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024